Gemigliptin L-tartrate Sesquihydrate/Glimepiride

吉格列汀酒石酸盐/格列美脲

Report date: 2022/01/14 13:23:58

Base Information

Drug NameGemigliptin L-tartrate Sesquihydrate/Glimepiride
Drug Alias Name格列美脲/吉格列汀酒石酸盐Gemigliptin/GlimepirideGlimepiride and Gemigliptin L-tartrate SesquihydrateGemigliptin L-tartrate Sesquihydrate and GlimepirideGlimepiride/gemigliptin
ClassificationSmall molecules
Mechanisms of ActionKATP channels blockersSulfonylurea receptor modulatorsDipeptidyl peptidase IV inhibitors
TargetsDipeptidyl peptidase IVSulfonylurea receptorKATP channels
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes Gemigliptin L-tartrate SesquihydrateGlimepiride
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesLg Chemical Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesLg Chemical Ltd
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksN/A